. Due to the metastases of cancer in the skeletal tissue, severe bone pain affects the quality of life of most patients suffering from malignancies of the breast, prostate, lungs, thyroid, or kidneys (2, 3). Although several interventions such as analgesics, bisphosphonates, hormone therapy, and systemic radionuclide therapy are available to manage the pain, these treatments are known to have many undesirable secondary effects (3). Radiopharmaceuticals that contain nuclides, such as strontium-89 (as 